Skip to main content
SpringerLink
Log in

Epidemiology and Outcomes of Non-albicans Candida Bloodstream Infections in Transplant Recipients and Cancer Patients

  • Original Article
  • Published:
Mycopathologia Aims and scope Submit manuscript

Abstract

We performed a retrospective survey of non-Candida albicans candidemia in patients with cancer, including those with solid tumors and those with hematological malignancies as well as transplants patients both, solid-organ transplant recipients and hematopoietic stem cell transplant recipients. The study was performed at two healthcare centers in New York City and covered the years 2018–2022. A total of 292 patients (318 isolates) were included in the study. In order of frequency, C. glabrata (38%) was the most common species recovered, followed by C. parapsilosis (19.2%), C. tropicalis (12.6%), C. krusei (10.7%), C. lusitaniae (5.7%), and C. guilliermondii (4.4%). Micafungin was the most common antifungal treatment and 18.5% of patients were on antifungal prophylaxis. The 30-day crude mortality was 40%. 4.5% of patients had more than one non-albicans species detected. In conclusion, this study represents one of the largest surveys of non-albicans species in cancer and transplant patients and provides data on the current epidemiology of these Candida species in this patient population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Vincent JL, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323–9.

    Article  CAS  PubMed  Google Scholar 

  2. Lyman M, et al. Worsening spread of Candida auris in the United States, 2019 to 2021. Ann Intern Med. 2023;176:489.

    Article  PubMed  Google Scholar 

  3. Bassetti M, et al. A multicenter study of septic shock due to candidemia: Outcomes and predictors of mortality. Intensiv Care Med. 2014;40(6):839–45.

    Article  CAS  Google Scholar 

  4. Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia: A systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis. 2006;25(7):419–25.

    Article  CAS  PubMed  Google Scholar 

  5. Garey KW, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. Clin Infect Dis. 2006;43(1):25–31.

    Article  CAS  PubMed  Google Scholar 

  6. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49(9):3640–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Zhang SX, et al. Multicenter evaluation of a PCR-based digital microfluidics and electrochemical detection system for the rapid identification of 15 fungal pathogens directly from positive blood cultures. J Clin Microbiol. 2020;58(5):e02096.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Huang TD, et al. Evaluation of the ePlex blood culture identification panels for detection of pathogens in bloodstream infections. J Clin Microbiol. 2019;57(2):e01597.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Southern TR, et al. Implementation and performance of the BioFire FilmArray(R) blood culture identification panel with antimicrobial treatment recommendations for bloodstream infections at a midwestern academic tertiary hospital. Diagn Microbiol Infect Dis. 2015;81(2):96–101.

    Article  PubMed  Google Scholar 

  10. Sparks R, et al. Evaluation of the BioFire blood culture identification 2 panel and impact on patient management and antimicrobial stewardship. Pathology. 2021;53(7):889–95.

    Article  PubMed  Google Scholar 

  11. Institute, C.A.L.S., CLSI. Performance Standards For Antifungal Susceptibility Testing Of Yeasts, in 2nd ed. CLSI supplement M60, Wayne, PA: Clinical and Laboratory Standards Institute; 2020.

  12. Institute, C.a.L.S., CLSI. Performance Standards for Antifungal Susceptibility Testing of Yeasts, in 3rd ed. CLSI supplement M27M44S, Wayne, PA: Clinical and Laboratory Standards Institute; 2022.

  13. Marcos-Zambrano LJ, et al. Candida guilliermondii complex is characterized by high antifungal resistance but low mortality in 22 cases of candidemia. Antimicrob Agents Chemother. 2017;61(7):e00099.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Pfaller MA, et al. Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: Geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol. 2006;44(10):3551–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Ngamchokwathana C, et al. Risk factors and outcomes of non-albicans Candida bloodstream infection in patients with candidemia at Siriraj Hospital-Thailand’s Largest National Tertiary Referral Hospital. J Fungi (Basel). 2021;7(4):269.

    Article  CAS  PubMed  Google Scholar 

  16. Pfaller MA, et al. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004–2008. PLoS ONE. 2014;9(7): e101510.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Andes DR, et al. The epidemiology and outcomes of invasive Candida infections among organ transplant recipients in the United States: Results of the transplant-associated infection surveillance network (TRANSNET). Transpl Infect Dis. 2016;18(6):921–31.

    Article  PubMed  Google Scholar 

  18. Lockhart SR, et al. Comparison of in vitro susceptibility characteristics of Candida species from cases of invasive candidiasis in solid organ and stem cell transplant recipients: Transplant-associated infections surveillance network (TRANSNET), 2001 to 2006. J Clin Microbiol. 2011;49(7):2404–10.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Pappas PG, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;62(4):e1-50.

    Article  PubMed  Google Scholar 

  20. Lehmann DM, et al. Analyzing Adherence to the 2016 infectious diseases society of America guidelines for candidemia in cancer patients. Open Forum Infect Dis. 2022;9(12):ofac555.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was funded in part by the MSK Cancer Center Support Grant /Core Grant (P30 CA008748).

Author information

Authors and Affiliations

  1. Department of Pathology, NYU Langone Health, New York, NY, USA

    Caitlin Otto

  2. Department of Pathology and Laboratory Medicine, Department of Medicine, Memorial Sloan Kettering Cancer Center, 327 East 64th Street CLM 522, New York, NY, 10065, USA

    N. Esther Babady

Authors
  1. Caitlin Otto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Esther Babady
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. Esther Babady.

Ethics declarations

Conflict of interest

The authors have not disclosed any competing interests.

Additional information

Handling Editor: Nancy Wengenack.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Otto, C., Babady, N.E. Epidemiology and Outcomes of Non-albicans Candida Bloodstream Infections in Transplant Recipients and Cancer Patients. Mycopathologia 188, 863–871 (2023). https://doi.org/10.1007/s11046-023-00765-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11046-023-00765-7

Keywords

Search

Navigation